Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company's commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis. The United States Food and Drug Administration (FDA) has granted orphan drug designation for KEVEYIS. The Company has a clinical-stage pipeline of therapies for endocrine diseases. The Company's lead compounds include COR-003 (levoketoconazole), a cortisol synthesis inhibitor, and COR-005 (veldoreotide), a somatostatin analog (SSA). The Company is studying COR-003 for the treatment of endogenous Cushing's syndrome. It is investigating COR-005 for the treatment of acromegaly. Both COR-003 and COR-005 have received orphan designation from the FDA and the European Medicines Agency (EMA).
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biopharmaceuticals
- Sub-Industry: N/A
- Symbol: NASDAQ:SBBP
- CUSIP: N/A
- Web: www.strongbridgebio.com
- Market Cap: $133.74 million
- Outstanding Shares: 35,335,000
- 50 Day Moving Avg: $6.01
- 200 Day Moving Avg: $4.27
- 52 Week Range: $2.00 - $7.89
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -7.45
- P/E Growth: 0.00
- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: $1.09 per share
- Price / Book: 6.56
- EBIDTA: ($34,900,000.00)
- Return on Equity: -55.12%
- Return on Assets: -32.84%
- Debt-to-Equity Ratio: 0.48%
- Current Ratio: 5.22%
- Quick Ratio: 5.22%
- Average Volume: 88,978 shs.
- Beta: 2.56
- Short Ratio: 6.28
Frequently Asked Questions for Strongbridge Biopharma PLC (NASDAQ:SBBP)
What is Strongbridge Biopharma PLC's stock symbol?
Strongbridge Biopharma PLC trades on the NASDAQ under the ticker symbol "SBBP."
How were Strongbridge Biopharma PLC's earnings last quarter?
Strongbridge Biopharma PLC (NASDAQ:SBBP) announced its quarterly earnings results on Tuesday, May, 16th. The company reported ($0.33) earnings per share for the quarter, topping analysts' consensus estimates of ($0.49) by $0.16. View Strongbridge Biopharma PLC's Earnings History.
When will Strongbridge Biopharma PLC make its next earnings announcement?
Where is Strongbridge Biopharma PLC's stock going? Where will Strongbridge Biopharma PLC's stock price be in 2017?
2 brokers have issued 1 year price objectives for Strongbridge Biopharma PLC's shares. Their forecasts range from $10.00 to $18.00. On average, they anticipate Strongbridge Biopharma PLC's stock price to reach $14.00 in the next twelve months. View Analyst Ratings for Strongbridge Biopharma PLC.
Are investors shorting Strongbridge Biopharma PLC?
Strongbridge Biopharma PLC saw a drop in short interest in July. As of July 14th, there was short interest totalling 811,894 shares, a drop of 23.1% from the June 30th total of 1,056,337 shares. Based on an average daily volume of 44,564 shares, the short-interest ratio is currently 18.2 days. Currently, 3.9% of the shares of the company are sold short.
Who are some of Strongbridge Biopharma PLC's key competitors?
Some companies that are related to Strongbridge Biopharma PLC include Fortress Biotech (FBIO), Peregrine Pharmaceuticals (PPHM), Kamada (KMDA), Mereo BioPharma Group PLC (MPH), MediWound (MDWD), Cardiome Pharma Corporation (CRME), Kadmon Holdings (KDMN), VIVUS (VVUS), Vericel Corporation (VCEL), Alimera Sciences (ALIM), KalVista Pharmaceuticals (KALV), Cesca Therapeutics (KOOL), Chiasma (CHMA), Mirna Therapeutics (MIRN), Tokai Pharmaceuticals (NVUS), Ocera Therapeutics (OCRX), Sonoma Pharmaceuticals (SNOA) and Onconova Therapeutics (ONTX).
Who are Strongbridge Biopharma PLC's key executives?
Strongbridge Biopharma PLC's management team includes the folowing people:
- John H. Johnson, Chairman of the Board
- Matthew Pauls J.D., Chief Executive Officer, Director
- A. Brian Davis, Chief Financial Officer
- Stephen J. Long, Chief Legal Officer
- Robert Lutz, Chief Business Officer
- Ruth Thieroff-Ekerdt M.D., Chief Medical Officer
- Richard S. Kollender, Director
- Garheng Kong M.D. Ph.D., Director
- Marten Steen, Director
- Hilde H Steineger, Director
Who owns Strongbridge Biopharma PLC stock?
How do I buy Strongbridge Biopharma PLC stock?
Shares of Strongbridge Biopharma PLC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Strongbridge Biopharma PLC's stock price today?
MarketBeat Community Rating for Strongbridge Biopharma PLC (NASDAQ SBBP)MarketBeat's community ratings are surveys of what our community members think about Strongbridge Biopharma PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Strongbridge Biopharma PLC stock can currently be purchased for approximately $7.15.
Earnings History for Strongbridge Biopharma PLC (NASDAQ:SBBP)Earnings History by Quarter for Strongbridge Biopharma PLC (NASDAQ SBBP)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for Strongbridge Biopharma PLC (NASDAQ:SBBP)
Current Year EPS Consensus Estimate: $-1.59 EPS
Next Year EPS Consensus Estimate: $-0.96 EPS
Dividend History for Strongbridge Biopharma PLC (NASDAQ:SBBP)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Strongbridge Biopharma PLC (NASDAQ:SBBP)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Strongbridge Biopharma PLC (NASDAQ:SBBP)
Latest Headlines for Strongbridge Biopharma PLC (NASDAQ:SBBP)
Strongbridge Biopharma PLC (SBBP) Chart for Thursday, July, 27, 2017